Ambaw Bellete

Vorsitzender bei

OncoSTING LLC

Vermögen: - $ am 31.05.2026

55 Jahre

10 Beziehungen

Health Technology

Technology Services

Consumer Services

Profil

Ambaw Bellete is currently Chairman at OncoSTING LLC and Director at Axiom REACH Foundation.
Former roles include President & Chief Operating Officer at CG Oncology, Inc. (2023–2026), Chief Executive Officer at Lion Healthcare Strategies LLC (2021–2023), Head-US Cancer Commercial Operations at Photocure ASA, Trustee at BioNJ, Inc., President at MCS, Inc. (2012–2019), Chief Operating Officer at FerGene, Inc., and President at Photocure, Inc. (2012–2019).
Education includes undergraduate studies at Murray State University (Kentucky).

Bekannte Unternehmensbeteiligungen

Unternehmen	Datum	Anzahl der Aktien	Bewertung	Datum der Bewertung
CG ONCOLOGY, INC. -.--%	15.04.2026	0 ( -.--% )	- $	31.05.2026

Aktive Positionen von Ambaw Bellete

Unternehmen	Position	Beginn
OncoSTING LLC OncoSTING LLC OncoSTING LLC is an American biotechnology company focused on developing immunotherapies for bladder cancer and certain solid tumors. The company is located in the US. Its lead product, OS-151, is a second-generation, recombinant BCG-based therapy that combines traditional BCG immunotherapy with sustained delivery of potent STING agonists. This dual-action approach is intended to enhance efficacy while reducing adverse events compared to standard BCG treatment. OS-151 is being developed primarily for non-muscle invasive bladder cancer and as an intratumoral immunotherapy for tumors such as malignant melanoma.	Vorsitzender	-

Alle aktiven Positionen von Ambaw Bellete

Ehemalige bekannte Positionen von Ambaw Bellete

Unternehmen	Position	Ende
CG ONCOLOGY, INC.	Präsident	-
Photocure, Inc. Photocure, Inc. Hospital/Nursing ManagementHealth Services Operates as a bladder cancer company	Präsident	01.08.2019
MCS, Inc. MCS, Inc. Information Technology ServicesTechnology Services Provides information systems and services to the home health care industry	Präsident	01.07.2019
FerGene, Inc. FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer	Präsident	-

Sehen Sie sich die Erfahrung von Ambaw Bellete im Detail an

Ausbildung von Ambaw Bellete

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Ambaw Bellete im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	8
MCS, Inc. MCS, Inc. Information Technology ServicesTechnology Services Provides information systems and services to the home health care industry	Technology Services
Photocure ASA Photocure ASA Medical SpecialtiesHealth Technology Develops and sells pharmaceuticals and medical devices	Health Technology
Murray State University (Kentucky) Murray State University (Kentucky) Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
BioNJ, Inc. BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services Promotes the biotechnology industry in New Jersey	Commercial Services
CG Oncology, Inc. CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic	Health Technology
Photocure, Inc. Photocure, Inc. Hospital/Nursing ManagementHealth Services Operates as a bladder cancer company	Health Services
FerGene, Inc. FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer	Health Technology
OncoSTING LLC OncoSTING LLC OncoSTING LLC is an American biotechnology company focused on developing immunotherapies for bladder cancer and certain solid tumors. The company is located in the US. Its lead product, OS-151, is a second-generation, recombinant BCG-based therapy that combines traditional BCG immunotherapy with sustained delivery of potent STING agonists. This dual-action approach is intended to enhance efficacy while reducing adverse events compared to standard BCG treatment. OS-151 is being developed primarily for non-muscle invasive bladder cancer and as an intratumoral immunotherapy for tumors such as malignant melanoma.